Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 Sep;93(Suppl 1):14–15. doi: 10.1111/j.1365-2249.1993.tb06218.x

Treatment of autoimmune diseases with normal immunoglobulin through manipulation of the idiotypic network.

N Ronda 1, S V Kaveri 1, M D Kazatchkine 1
PMCID: PMC1554928  PMID: 8365019

Full text

PDF
14

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adib M., Ragimbeau J., Avrameas S., Ternynck T. IgG autoantibody activity in normal mouse serum is controlled by IgM. J Immunol. 1990 Dec 1;145(11):3807–3813. [PubMed] [Google Scholar]
  2. Berchtold P., Dale G. L., Tani P., McMillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood. 1989 Nov 15;74(7):2414–2417. [PubMed] [Google Scholar]
  3. Bussel J. B., Kimberly R. P., Inman R. D., Schulman I., Cunningham-Rundles C., Cheung N., Smithwick E. M., O'Malley J., Barandun S., Hilgartner M. W. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood. 1983 Aug;62(2):480–486. [PubMed] [Google Scholar]
  4. Dietrich G., Algiman M., Sultan Y., Nydegger U. E., Kazatchkine M. D. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood. 1992 Jun 1;79(11):2946–2951. [PubMed] [Google Scholar]
  5. Dietrich G., Kaveri S. V., Kazatchkine M. D. A V region-connected autoreactive subfraction of normal human serum immunoglobulin G. Eur J Immunol. 1992 Jul;22(7):1701–1706. doi: 10.1002/eji.1830220706. [DOI] [PubMed] [Google Scholar]
  6. Dietrich G., Kazatchkine M. D. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest. 1990 Mar;85(3):620–625. doi: 10.1172/JCI114483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hurez V., Kaveri S. V., Kazatchkine M. D. Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur J Immunol. 1993 Apr;23(4):783–789. doi: 10.1002/eji.1830230402. [DOI] [PubMed] [Google Scholar]
  8. Jayne D. R., Davies M. J., Fox C. J., Black C. M., Lockwood C. M. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991 May 11;337(8750):1137–1139. doi: 10.1016/0140-6736(91)92797-6. [DOI] [PubMed] [Google Scholar]
  9. Ronda N., Hurez V., Kazatchkine M. D. Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang. 1993;64(2):65–72. doi: 10.1111/j.1423-0410.1993.tb02521.x. [DOI] [PubMed] [Google Scholar]
  10. Rossi F., Sultan Y., Kazatchkine M. D. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol. 1988 Nov;74(2):311–316. [PMC free article] [PubMed] [Google Scholar]
  11. Sultan Y., Kazatchkine M. D., Maisonneuve P., Nydegger U. E. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984 Oct 6;2(8406):765–768. doi: 10.1016/s0140-6736(84)90701-3. [DOI] [PubMed] [Google Scholar]
  12. Sultan Y., Rossi F., Kazatchkine M. D. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci U S A. 1987 Feb;84(3):828–831. doi: 10.1073/pnas.84.3.828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Varela F., Andersson A., Dietrich G., Sundblad A., Holmberg D., Kazatchkine M., Coutinho A. Population dynamics of natural antibodies in normal and autoimmune individuals. Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5917–5921. doi: 10.1073/pnas.88.13.5917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. van Doorn P. A., Rossi F., Brand A., van Lint M., Vermeulen M., Kazatchkine M. D. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1990 Sep-Oct;29(1-3):57–64. doi: 10.1016/0165-5728(90)90147-f. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES